Aplastic anemia

Active Research Protocols

  1. 00-H-0032 – Treatment of Severe Aplastic Anemia with Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)
  2. 00-H-0169 – A Phase II Study of Antithymocyte Globulin (ATG) and Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
  3. 02-C-0052 – Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
  4. 03-H-0051 – Collection of Blood, Stool, Bone Marrow and/or Tissue Samples from Subjects with Hepatitis-Associated Aplastic Anemia
  5. 03-H-0193 – A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects with Severe Aplastic Anemia
  6. 03-H-0249 – A Randomized Trial of Immunosupression in Aplastic Anemia Patients with Refractory Pancytopenia or Suboptimal Hematologic Response after h-ATG/CsA Treatment
  7. 04-H-0213 – Cytokine Gene Polymorphisms in Bone Marrow Failure
  8. 05-H-0206 – A Pilot Study of Alemtuzumab (Campath[R]) in Patients with Myelodysplastic Syndrome (MDS)
  9. 05-H-0242 – A Pilot Study of Alemtuzumab (Campath) in Patients with Relapsed or Refractory Severe Aplastic Anemia
  10. 06-H-0034 – A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients with Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab
  11. 08-H-0046 – Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy
  12. 09-H-0154 – A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Aplastic Anemia Patients with Immunosuppressive-Therapy Refractory Thrombocytopenia
  13. 09-H-0183 – Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or with a Suboptimal Response to Rabbit ATG/CsA Treatment
  14. 10-H-0154 – Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-Cells
  15. 10-H-0176 – Cyclophosphamide Plus Cyclosporine in Treatment-Na•ve Severe Aplastic Anemia
  16. 10-H-0177 – A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
  17. 11-H-0134 – A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients
  18. 11-H-0209 – Male Hormones for Telomere Related Diseases
  19. 12-CC-0096 – Collection of Granulocytes by Apheresis of Healthy Donors Stimulated with Filgrastim (G-CSF) and Dexamethasone
  20. 12-H-0150 – Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
  21. 13-CC-0161 – A Description of the Oral Microbiome of Patients with Severe Aplastic Anemia
  22. 13-H-0116 – A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
  23. 13-H-0133 – Extended Dosing with Eltrombopag in Refractory Severe Aplastic Anemia
  24. 86-H-0088 – Lymphocytapheresis of Patients with Pancytopenia
  25. 97-H-0117 – A Randomized Trial of Antithymocyte Globulin and Cyclosporine versus Cyclophosphamide and Cyclosporine in the Treatment of Severe Aplastic Anemia
  26. 97-H-0130 – Collection of Blood and Bone Marrow from Healthy Volunteers and Patients for Research Purposes
  27. 99-H-0050 – Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014